OncoMed Pharmaceuticals (OMED) Crumbles: Stock Falls by 5.6% - Tale of the Tape
OncoMed Pharmaceuticals, Inc. (OMED) saw a big move last session, as the company’s shares fell by about 6% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for OMED, as the stock is now down around 8% since Dec 9.
This development-stage biotechnology company has seen a flat track record when it comes to current year estimate revisions over the past few weeks (0 increases, 0 decreases), and the consensus for loss hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future, and especially on earnings estimates following the recent slump.
OMED currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked stock in the Med-Biomed/Generic industry include Affymetrix Inc. (AFFX), carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ONCOMED PHARMA (OMED): Free Stock Analysis Report
AFFYMETRIX INC (AFFX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
